{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:14:11Z","timestamp":1791288851916,"version":"4.3.0"},"reference-count":31,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava\n            <jats:sup>\u00ae<\/jats:sup>\n            IV, Mitsubishi Tanabe Pharma America [MTPA], hereafter \u201cIV edaravone\u201d) in a real-world setting.\n            <jats:bold>Background:<\/jats:bold>\n            IV edaravone is US FDA approved for the treatment of ALS and was shown in clinical trials to slow the rate of physical functional decline.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            This retrospective observational analysis included PALS continuously enrolled in Optum's Clinformatics\n            <jats:sup>\u00ae<\/jats:sup>\n            Data Mart between 8 August 2017 and 31 December 2021. Cases treated with IV edaravone and controls not treated with IV edaravone were propensity score matched for: age, sex, race, US region of residence, pre-index disease duration, insurance, riluzole prescription; and pre-index claims for cardiovascular disease, artificial nutrition\/gastrostomy tube, noninvasive ventilation and all-cause hospitalization. The index date was the first IV edaravone claim for cases; for controls, the index date was randomly assigned after IV edaravone market availability. Restricted mean time lost was calculated for the following disease progression milestones: new use of canes\/walkers\/wheelchairs, artificial nutrition, noninvasive ventilation, invasive ventilation, speech-generating devices and hospice.\n            <jats:bold>Results:<\/jats:bold>\n            Cases (n\u00a0=\u00a0395) were matched to controls (n\u00a0=\u00a0395). Cases had less restricted mean time lost, indicating longer disease progression milestone-free time, for all disease progression milestones. From 0 to 24\u00a0months post index, more cases (n\u00a0=\u00a0129) than controls (n\u00a0=\u00a0103) reported no milestones and more controls (n\u00a0=\u00a0232) than cases (n\u00a0=\u00a0131) reported deaths.\n            <jats:bold>Conclusion:<\/jats:bold>\n            In a US-based real-world setting, IV edaravone-treated PALS had a longer time to disease progression milestone events and fewer deaths in 2 years compared with PALS not treated with IV edaravone.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0007","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:16:14Z","timestamp":1737987374000},"source":"Crossref","is-referenced-by-count":3,"title":["Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-6081","authenticated-orcid":false,"given":"James D","family":"Berry","sequence":"first","affiliation":[{"name":"Healey Center for ALS, Massachusetts General Hospital, Neurology, Boston, MA, 02114 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6677-0662","authenticated-orcid":false,"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[{"name":"Mitsubishi Tanabe Pharma America, Inc., Health Economics and Outcomes Research (HEOR), Medical Affairs, Jersey City, NJ, 07310 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-0444","authenticated-orcid":false,"given":"Jeffrey","family":"Zhang","sequence":"additional","affiliation":[{"name":"Princeton Pharmatech, LLC, Biostatistics, Princeton, NJ, 08550 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Princeton Pharmatech, LLC, Biostatistics, Princeton, NJ, 08550 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Ciepielewska","sequence":"additional","affiliation":[{"name":"Mitsubishi Tanabe Pharma America, Inc., Health Economics and Outcomes Research (HEOR), Medical Affairs, Jersey City, NJ, 07310 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown RH","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377(2), 162\u2013172 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_8_4_2","first-page":"S175","article-title":"Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy \u2013 a roundtable discussion","volume":"24","author":"Brooks BR","year":"2018","unstructured":"Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy \u2013 a roundtable discussion. Am. J. Manag. Care 24(Suppl. 9), S175\u2013S186 (2018).","journal-title":"Am. J. Manag. Care"},{"issue":"1","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/21678421.2022.2059380","article-title":"Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017","volume":"24","author":"Mehta P","year":"2023","unstructured":"Mehta P, Raymond J, Punjani R Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph. Lateral Scler. Frontotemporal Degener. 24(1\u20132), 108\u2013116 (2023).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"e_1_3_8_6_2","volume-title":"Prescribing information.","author":"Rilutek\u00ae (riluzole)","year":"2016","unstructured":"Rilutek\u00ae (riluzole). Prescribing information. Covis Pharmaceuticals, Inc, NC, USA (2016)."},{"key":"e_1_3_8_7_2","volume-title":"Prescribing Information.","author":"Radicava\u00ae (edaravone) injection and Radicava ORS\u00ae (edaravone) oral suspension","year":"2022","unstructured":"Radicava\u00ae (edaravone) injection and Radicava ORS\u00ae (edaravone) oral suspension. Prescribing Information. Mitsubishi Tanabe Pharma Corporation, NJ, USA (2022)."},{"issue":"7","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Writing Group; Edaravone (MCI-186) ALS 19 Study Group","year":"2017","unstructured":"Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16(7), 505\u2013512 (2017).","journal-title":"Lancet Neurol."},{"key":"e_1_3_8_9_2","volume-title":"Prescribing information.","author":"Relyvrio\u00ae (sodium phenylbutyrate and taurursodiol)","year":"2022","unstructured":"Relyvrio\u00ae (sodium phenylbutyrate and taurursodiol). Prescribing information. Amylyx Pharmaceuticals, Inc, MA ,USA (2022)."},{"key":"e_1_3_8_10_2","volume-title":"Prescribing information.","author":"QALSODY\u00ae (tofersen) injection","year":"2023","unstructured":"QALSODY\u00ae (tofersen) injection. Prescribing information. Biogen MA Inc, MA, USA (2023)."},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4297"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1658"},{"key":"e_1_3_8_13_2","unstructured":"US Food and Drug Administration. Framework for FDA's real-world evidence program. (2018) (Accessed 10 February 2023). https:\/\/www.fda.gov\/media\/120060\/download"},{"issue":"10","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative","volume":"143","author":"Franklin JM","year":"2021","unstructured":"Franklin JM, Patorno E, Desai RJ Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative. Circulation 143(10), 1002\u20131013 (2021).","journal-title":"Circulation"},{"key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"101590","DOI":"10.1016\/j.eclinm.2022.101590","article-title":"Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis","volume":"52","author":"Brooks BR","year":"2022","unstructured":"Brooks BR, Berry JD, Ciepielewska M Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis. EClinicalMedicine 52, 101590 (2022).","journal-title":"EClinicalMedicine"},{"issue":"9","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/aje\/kwq224","article-title":"Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score","volume":"172","author":"Austin PC","year":"2010","unstructured":"Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am. J. Epidemiol. 172(9), 1092\u20131097 (2010).","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart EA","year":"2013","unstructured":"Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J. Clin. Epidemiol. 66(Suppl. 8), S84\u2013S90; e1 (2013).","journal-title":"J. Clin. Epidemiol."},{"issue":"9","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/sim.8896","article-title":"Estimation and modeling of the restricted mean time lost in the presence of competing risks","volume":"40","author":"Conner SC","year":"2021","unstructured":"Conner SC, Trinquart L. Estimation and modeling of the restricted mean time lost in the presence of competing risks. Stat. Med. 40(9), 2177\u20132196 (2021).","journal-title":"Stat. Med."},{"issue":"1","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"20220035","DOI":"10.1515\/jci-2022-0035","article-title":"Matched design for marginal causal effect on restricted mean survival time in observational studies","volume":"11","author":"Lin Z","year":"2023","unstructured":"Lin Z, Ni A, Lu B. Matched design for marginal causal effect on restricted mean survival time in observational studies. J. Caus. Infer. 11(1), 20220035 (2023).","journal-title":"J. Caus. Infer."},{"issue":"3","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/EDE.0000000000000457","article-title":"Sensitivity analysis without assumptions","volume":"27","author":"Ding P","year":"2016","unstructured":"Ding P, VanderWeele TJ. Sensitivity analysis without assumptions. Epidemiology 27(3), 368\u2013377 (2016).","journal-title":"Epidemiology"},{"issue":"4","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele TJ","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167(4), 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III)","volume":"169","author":"Cedarbaum JM","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J. Neurol. Sci. 169(1\u20132), 13\u201321 (1999).","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/21678421.2016.1140786","article-title":"The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset","volume":"17","author":"Proudfoot M","year":"2016","unstructured":"Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph. Lateral Scler. Frontotemporal Degener. 17(5\u20136), 414\u2013425 (2016).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"issue":"1","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/17482968.2010.502940","article-title":"The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials","volume":"12","author":"Beghi E","year":"2011","unstructured":"Beghi E, Chio A, Couratier P The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. 12(1), 1\u201310 (2011).","journal-title":"Amyotroph. Lateral Scler."},{"issue":"3","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/21678421.2014.897357","article-title":"Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale","volume":"5","author":"Balendra R","year":"2014","unstructured":"Balendra R, Jones A, Jivraj N Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener. 5(3\u20134), 279\u2013284 (2014).","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"issue":"1","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/WNL.59.1.99","article-title":"Early symptom progression rate is related to ALS outcome: a prospective population-based study","volume":"59","author":"Chio A","year":"2002","unstructured":"Chio A, Mora G, Leone M Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59(1), 99\u2013103 (2002).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2008.07.016","article-title":"ALSFRS-R score and its ratio: a useful predictor for ALS-progression","volume":"275","author":"Kollewe K","year":"2008","unstructured":"Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J. Neurol. Sci. 275(1\u20132), 69\u201373 (2008).","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/brain\/awr351","article-title":"A proposed staging system for amyotrophic lateral sclerosis","volume":"135","author":"Roche JC","year":"2012","unstructured":"Roche JC, Rojas-Garcia R, Scott KM A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3), 847\u2013852 (2012).","journal-title":"Brain"},{"issue":"3","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/21678421.2016.1265565","article-title":"Comparison of the King's and MiToS staging systems for ALS","volume":"18","author":"Fang T","year":"2017","unstructured":"Fang T, Al Khleifat A, Stahl DR Comparison of the King's and MiToS staging systems for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 18(3\u20134), 227\u2013232 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"issue":"3","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00415-019-09199-y","article-title":"Tollgate-based progression pathways of ALS patients","volume":"266","author":"Dalgic OO","year":"2019","unstructured":"Dalgic OO, Erenay FS, Pasupathy KS, Ozaltin OY, Crum BA, Sir MY. Tollgate-based progression pathways of ALS patients. J. Neurol. 266(3), 755\u2013765 (2019).","journal-title":"J. Neurol."},{"key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"103895","DOI":"10.1016\/j.jbi.2021.103895","article-title":"Mapping of critical events in disease progression through binary classification: application to amyotrophic lateral sclerosis","volume":"123","author":"Dalgic OO","year":"2021","unstructured":"Dalgic OO, Wu H, Safa Erenay F Mapping of critical events in disease progression through binary classification: application to amyotrophic lateral sclerosis. J. Biomed. Inform. 123, 103895 (2021).","journal-title":"J. Biomed. Inform."},{"issue":"1","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/aje\/kwab235","article-title":"Implementation of an alternative method for assessing competing risks: restricted mean time lost","volume":"191","author":"Wu H","year":"2022","unstructured":"Wu H, Yuan H, Yang Z, Hou Y, Chen Z. Implementation of an alternative method for assessing competing risks: restricted mean time lost. Am. J. Epidemiol. 191(1), 163\u2013172 (2022).","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/21678421.2023.2165947","article-title":"Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review","volume":"24","author":"Berry JD","year":"2023","unstructured":"Berry JD, Blanchard M, Bonar K Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review. Amyotroph. Lateral Scler. Frontotemporal Degener. 24(5-6), 436\u2013448 (2023).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:07:37Z","timestamp":1738066057000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.57264\/cer-2024-0007"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0007","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"article-number":"e240007"}}